Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer vaccines in combination with additional treatment modalities.

Literature DB >> 24838261

Prostate cancer vaccines in combination with additional treatment modalities.

Matthew A Uhlman¹, Megan T Bing, David M Lubaroff.

Abstract

Immunotherapy has been investigated in both preclinical studies and clinical trials as a new therapy for prostate cancer. Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase. The vaccines have long been studied as monotherapy for the cancer, but increasingly more trials have been initiated in combination with other modalities. These include radiation, chemotherapy, and androgen deprivation therapy. This review describes and discusses the various combinations of vaccine immunotherapies.

Entities: Chemical

Mesh：

Substances：
Cancer Vaccines

Year: 2014 PMID： 24838261 DOI： 10.1007/s12026-014-8532-1

Source DB: PubMed Journal: Immunol Res ISSN： 0257-277X Impact factor: 4.505

49 in total

1. Immunotherapy for prostate cancer: walk, don't run.

Authors: Charles G Drake
Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544

2. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.

Authors: M Kamrava; A H Kesarwala; R A Madan; E Lita; A Kaushal; K-Y Tsang; D J Poole; S M Steinberg; T Ferrara; W Dahut; J Schlom; J L Gulley
Journal: Prostate Cancer Prostatic Dis Date: 2012-03-06 Impact factor: 5.554

3. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors: James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531

Review 4. Recent advances revolutionize treatment of metastatic prostate cancer.

Authors: Ravi A Madan; Philip M Arlen
Journal: Future Oncol Date: 2013-08 Impact factor: 3.404

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal: Lancet Date: 2010-10-02 Impact factor: 79.321

6. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection.

Authors: George Miller; Svenja Lahrs; Venu G Pillarisetty; Alaap B Shah; Ronald P DeMatteo
Journal: Cancer Res Date: 2002-09-15 Impact factor: 12.701

7. Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245

8. Update on options for treatment of metastatic castration-resistant prostate cancer.

Authors: Prakash Vishnu; Winston W Tan
Journal: Onco Targets Ther Date: 2010-06-24 Impact factor: 4.147

9. Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy.

Authors: Susan R Slovin
Journal: Front Oncol Date: 2012-05-30 Impact factor: 6.244

10. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

Authors: Nadeem A Sheikh; Daniel Petrylak; Philip W Kantoff; Corazon Dela Rosa; Frances P Stewart; Ling-Yu Kuan; James B Whitmore; James B Trager; Christian H Poehlein; Mark W Frohlich; David L Urdal
Journal: Cancer Immunol Immunother Date: 2012-08-03 Impact factor: 6.968

9 in total

1. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

Authors: V Riabov; I Tretyakova; R B Alexander; P Pushko; E N Klyushnenkova
Journal: Vaccine Date: 2015-08-28 Impact factor: 3.641

2. The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study.

Authors: Bao-Chi Chang; Shyh-Jen Wang
Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452

Prostate cancer vaccines in combination with additional treatment modalities.

1. Immunotherapy for prostate cancer: walk, don't run.

2. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.

3. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Review 4. Recent advances revolutionize treatment of metastatic prostate cancer.

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

6. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection.

7. Abiraterone in metastatic prostate cancer without previous chemotherapy.

8. Update on options for treatment of metastatic castration-resistant prostate cancer.

9. Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy.

10. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

1. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

2. The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study.

Review 3. Translational research in oncology--10 years of progress and future prospects.

Review 4. Oncolytic virotherapy for urological cancers.

Review 5. From bench to bedside: immunotherapy for prostate cancer.

Review 6. Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.

Review 7. Immune Infiltration and Prostate Cancer.

Review 8. Natriuretic Peptides: The Case of Prostate Cancer.

Review 9. Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.